OncoCyte (NAS:OCX) Change In Receivables

: $-0.96 Mil (TTM As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

OncoCyte's change in receivables for the quarter that ended in Sep. 2022 was $-0.19 Mil. It means OncoCyte's Accounts Receivable increased by $0.19 Mil from Jun. 2022 to Sep. 2022 .

OncoCyte's change in receivables for the fiscal year that ended in Dec. 2021 was $-1.23 Mil. It means OncoCyte's Accounts Receivable increased by $1.23 Mil from Dec. 2020 to Dec. 2021 .

OncoCyte's Accounts Receivable for the quarter that ended in Sep. 2022 was $1.99 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. OncoCyte's Days Sales Outstanding for the three months ended in Sep. 2022 was 178.55.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. OncoCyte's liquidation value for the three months ended in Sep. 2022 was $-46.52 Mil.

OncoCyte Change In Receivables Historical Data

The historical data trend for OncoCyte's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Receivables

-0.18

-1.23

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Receivables																-0.01	-0.41	-0.69	0.32	-0.19

OncoCyte Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96 Mil.

OncoCyte (NAS:OCX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

OncoCyte's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.99	/	1.017	*	91
=	178.55

2. In Ben Graham's calculation of liquidation value, OncoCyte's accounts receivable are only considered to be worth 75% of book value:

OncoCyte's liquidation value for the quarter that ended in Sep. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	32.472	-	80.487	+	0.75 * 1.99	+	0.5 * 0
=	-46.52

OncoCyte Change In Receivables Related Terms

Thank you for viewing the detailed overview of OncoCyte's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund	director	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen	officer: Chief Operating Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross	officer: Chief Medical Officer	15 CUSHING, IRVINE CA 92618
Tony T Kalajian	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008